Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05228015
Title Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ikena Oncology
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GBR

Facility Status City State Zip Country Details
The University of Chicago Chicago Illinois 60637 United States Details
Massachusetts General Hospital Boston Massachusetts 02215 United States Details
Start Midwest Grand Rapids Michigan 49546 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
University of Pennsylvania Abramson Cancer Center Philadelphia Pennsylvania 19104 United States Details
Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital Philadelphia Pennsylvania 19107 United States Details
Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Next Oncology San Antonio Texas 78229 United States Details
University Hospitals of Leicester NHS Trust Leicester England LE1 5WW United Kingdom Details
The Royal Marsden Hospital London England SW3 6JJ United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field